Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
Identifieur interne : 001207 ( Ncbi/Checkpoint ); précédent : 001206; suivant : 001208Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
Auteurs : William G. Ondo [États-Unis] ; Ron Tintner ; Kevin Dat Voung ; Dejian Lai ; George RingholzSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antipsychotic Agents (adverse effects), Brief Psychiatric Rating Scale, Dibenzothiazepines (adverse effects), Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Evaluation, Female, Hallucinations (chemically induced), Humans, Male, Middle Aged, Neuropsychological Tests, Parkinson Disease (drug therapy), Placebos, Questionnaires, Treatment Outcome.
- MESH :
- chemical , adverse effects : Antipsychotic Agents, Dibenzothiazepines.
- chemically induced : Hallucinations.
- drug therapy : Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Brief Psychiatric Rating Scale, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Evaluation, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Placebos, Questionnaires, Treatment Outcome.
Abstract
We completed a single site, double-blind, placebo-controlled, parallel design study of quetiapine for hallucinations in PD. Thirty-one subjects with PD and prominent visual hallucinations and Mini-Mental State Examination score >21 were randomly assigned in a 2:1 drug to placebo ratio, up to 200 mg daily of quetiapine or matching placebo given in two doses. They were seen at 3 weeks (100 mg/day) and 12 weeks (200 mg/day, with optional dose reduction). Evaluation included the Unified Parkinson's Disease Rating Scale (UPDRS), the Baylor PD Hallucination Questionnaire, and a battery of neuropsychological tests. The demographics between subjects randomized to drug (n = 21) vs. placebo (n = 10) were similar. The final dose of active drug was 200 (n = 11), 150 (n = 2), 100 (n = 3), and 75 (n = 1) mg per day. All placebo subjects were on the equivalent of 200 mg per day. The UPDRS Activities of Daily Living and Motor scores did not significantly change compared to placebo. Compared to placebo, there were no significant changes in our hallucination questionnaire, the Brief Psychiatric Rating Scale (BPRS), or question 12 (hallucination item) of the BPRS. There were no significant changes on any of the neuropsychological measures. Adverse events on drug included sedation (n = 9), but no drug-related adverse events precipitated discontinuation and none were rated as serious. Quetiapine, up to 200 mg daily, was well tolerated and did not worsen UPDRS scores; however, there was no significant improvement in psychosis rating scales compared to placebo. Larger doses of drug and greater sample sizes might be considered in future studies.
DOI: 10.1002/mds.20474
PubMed: 15800937
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003094
- to stream PubMed, to step Curation: 003094
- to stream PubMed, to step Checkpoint: 003159
- to stream Ncbi, to step Merge: 001207
- to stream Ncbi, to step Curation: 001207
Links to Exploration step
pubmed:15800937Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.</title><author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G" last="Ondo">William G. Ondo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA. wondo@bcm.tmc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas 77030</wicri:regionArea><wicri:noRegion>Texas 77030</wicri:noRegion></affiliation></author><author><name sortKey="Tintner, Ron" sort="Tintner, Ron" uniqKey="Tintner R" first="Ron" last="Tintner">Ron Tintner</name></author><author><name sortKey="Voung, Kevin Dat" sort="Voung, Kevin Dat" uniqKey="Voung K" first="Kevin Dat" last="Voung">Kevin Dat Voung</name></author><author><name sortKey="Lai, Dejian" sort="Lai, Dejian" uniqKey="Lai D" first="Dejian" last="Lai">Dejian Lai</name></author><author><name sortKey="Ringholz, George" sort="Ringholz, George" uniqKey="Ringholz G" first="George" last="Ringholz">George Ringholz</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="doi">10.1002/mds.20474</idno><idno type="RBID">pubmed:15800937</idno><idno type="pmid">15800937</idno><idno type="wicri:Area/PubMed/Corpus">003094</idno><idno type="wicri:Area/PubMed/Curation">003094</idno><idno type="wicri:Area/PubMed/Checkpoint">003159</idno><idno type="wicri:Area/Ncbi/Merge">001207</idno><idno type="wicri:Area/Ncbi/Curation">001207</idno><idno type="wicri:Area/Ncbi/Checkpoint">001207</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.</title><author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G" last="Ondo">William G. Ondo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA. wondo@bcm.tmc.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas 77030</wicri:regionArea><wicri:noRegion>Texas 77030</wicri:noRegion></affiliation></author><author><name sortKey="Tintner, Ron" sort="Tintner, Ron" uniqKey="Tintner R" first="Ron" last="Tintner">Ron Tintner</name></author><author><name sortKey="Voung, Kevin Dat" sort="Voung, Kevin Dat" uniqKey="Voung K" first="Kevin Dat" last="Voung">Kevin Dat Voung</name></author><author><name sortKey="Lai, Dejian" sort="Lai, Dejian" uniqKey="Lai D" first="Dejian" last="Lai">Dejian Lai</name></author><author><name sortKey="Ringholz, George" sort="Ringholz, George" uniqKey="Ringholz G" first="George" last="Ringholz">George Ringholz</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antipsychotic Agents (adverse effects)</term><term>Brief Psychiatric Rating Scale</term><term>Dibenzothiazepines (adverse effects)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Evaluation</term><term>Female</term><term>Hallucinations (chemically induced)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Parkinson Disease (drug therapy)</term><term>Placebos</term><term>Questionnaires</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term><term>Dibenzothiazepines</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hallucinations</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Brief Psychiatric Rating Scale</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Evaluation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Placebos</term><term>Questionnaires</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We completed a single site, double-blind, placebo-controlled, parallel design study of quetiapine for hallucinations in PD. Thirty-one subjects with PD and prominent visual hallucinations and Mini-Mental State Examination score >21 were randomly assigned in a 2:1 drug to placebo ratio, up to 200 mg daily of quetiapine or matching placebo given in two doses. They were seen at 3 weeks (100 mg/day) and 12 weeks (200 mg/day, with optional dose reduction). Evaluation included the Unified Parkinson's Disease Rating Scale (UPDRS), the Baylor PD Hallucination Questionnaire, and a battery of neuropsychological tests. The demographics between subjects randomized to drug (n = 21) vs. placebo (n = 10) were similar. The final dose of active drug was 200 (n = 11), 150 (n = 2), 100 (n = 3), and 75 (n = 1) mg per day. All placebo subjects were on the equivalent of 200 mg per day. The UPDRS Activities of Daily Living and Motor scores did not significantly change compared to placebo. Compared to placebo, there were no significant changes in our hallucination questionnaire, the Brief Psychiatric Rating Scale (BPRS), or question 12 (hallucination item) of the BPRS. There were no significant changes on any of the neuropsychological measures. Adverse events on drug included sedation (n = 9), but no drug-related adverse events precipitated discontinuation and none were rated as serious. Quetiapine, up to 200 mg daily, was well tolerated and did not worsen UPDRS scores; however, there was no significant improvement in psychosis rating scales compared to placebo. Larger doses of drug and greater sample sizes might be considered in future studies.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Lai, Dejian" sort="Lai, Dejian" uniqKey="Lai D" first="Dejian" last="Lai">Dejian Lai</name><name sortKey="Ringholz, George" sort="Ringholz, George" uniqKey="Ringholz G" first="George" last="Ringholz">George Ringholz</name><name sortKey="Tintner, Ron" sort="Tintner, Ron" uniqKey="Tintner R" first="Ron" last="Tintner">Ron Tintner</name><name sortKey="Voung, Kevin Dat" sort="Voung, Kevin Dat" uniqKey="Voung K" first="Kevin Dat" last="Voung">Kevin Dat Voung</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G" last="Ondo">William G. Ondo</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001207 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001207 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:15800937
|texte= Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:15800937" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |